Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks We're Ready to Buy Again

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Our Foolish contributors think the market's wild ways have transformed these three stocks into compelling bargains.

Source: Pixabay.

Stocks have been on a wild ride so far this year, because of the confluence of falling oil prices and the ongoing U.S. presidential election. Our Foolish contributors, though, think that this volatility has created some compelling buying opportunities for patient investors. Read on to find out which three stocks they're buying again, and why they're doing so. 

Neha Chamaria: This will probably be a tough year for Potash Corporation of Saskatchewan (POT), as demand for fertilizers continues to exceed supply, but much of the pessimism appears to be baked into the stock price. Having lost half its value in the past year, PotashCorp is currently trading close to its 52-week lows and commanding historically low valuations.

POT PE Ratio (TTM) Chart

POT P/E Ratio (TTM) data by YCharts

That looks like a compelling opportunity to get into a company that manufactures fertilizers that help improve crop productivity -- an urgent need in this hour of erratic climate changes, shrinking arable land, and a growing population.

According to the latest industry updates, India -- a key market for potash -- will probably call off its potash import holiday earlier than planned and negotiate contracts in a few weeks' time. Meanwhile, prices of key crop corn have climbed steadily in recent months in anticipation of lower yields from Brazil, and projections for the U.S. corn acreage have bumped up, too. That's encouraging for PotashCorp, because corn requires large amounts of fertilizers, and higher crop prices boost farmers' income and demand for nutrients.

It also helps that PotashCorp is striving hard to boost margins while it awaits the end markets to turn around. For instance, it is aggressively ramping up its lowest-cost plant at Rocanville to bring down its cost of production substantially in the near future. 

Long story short, PotashCorp may grow slowly, but I don't see much downside in its earnings in the years to come. At barely 10 times trailing earnings and a dividend yield that tops 5%, I'm willing to stomach some of the volatility and bet on the stock today for greater long-term returns.

George Budwell: I'm currently buying shares of Allergan (AGN), again, for a couple of reasons. First off, Allergan's stock absolutely crumbled after its planned merger with Pfizer went south earlier this month. And while such a dramatic downturn may normally be cause for concern, I think it represents an amazing opportunity to buy a quality company at a substantial discount. In fact, Allergan's shares are currently trading near their 52-week lows and are down by over 35% from their former highs, according to data provided by S&P Global Market Intelligence:

AGN Chart

AGN data by YCharts

Besides its far lower share price compared with just a few months ago, I think Allergan's diverse branded pharma portfolio, which sports medical aesthetics products such as Botox, the chronic-dry-eye drug Restasis, and the Alzheimer's disease treatment Namenda XR, is worth a deeper dive by value investors. All three of these products posted double-digit annual sales growth last year, helping to drive Allergan's total revenues up by 10% on a pro forma basis in 2015. And with multiple commercial launches for newer products such as the double-chin treatment Kybella and the novel antibiotic Dalvance under way, Allergan looks, to me, like it offers considerable deep value for patient shareholders as well.

Allergan's shares were performing admirably before this merger with Pfizer was even announced -- primarily because of its top-flight product portfolio and compelling long-term growth profile. That's why I think the market will eventually forget about this botched merger with Pfizer and remember that Allergan remains a solid stand alone investing vehicle. .  

Steve Symington: When I bought my first shares of Whole Foods Market (WFM) almost exactly three years ago, I wrote at the time that I intended to hold the stock in my personal portfolio for at least a decade. And even with shares down around 40% from their 52-week-high -- and roughly 30% below my original cost basis -- my resolve to continue buying and holding Whole Foods stock hasn't changed. In fact, I think now is a great time for investors to open or add to their positions in Whole Foods.

That's not to say the organic grocer's business isn't facing some legitimate concerns. Competition for its lucrative niche has continued to intensify as both smaller organic grocers and entrenched traditional competitors expand their presence, which means Whole Foods has had to focus more on value-oriented items and, in turn, take a hit on margins. But Whole Foods also unveiled a nine-point plan this past November to differentiate itself, including notable near-term goals of improving its cost structure, technology and strategic marketing investments, building consumers' perception of Whole Foods' value proposition and brand differentiation, and next month's launch of its first store featuring the new smaller footprint 365 concept, which holds promise to drive growth with modern designs, innovative technology, and carefully curated product mixes.

That's not mention Whole Foods sees the potential to nearly triple its U.S. store base to 1,200 locations over the long term, and that number could increase further depending on the success of the 365 concept. So even in the face of stiff competition and less lucrative margins than we've seen in the past, Whole Foods should still be able to drive shareholder value by combining that sheer growth potential with its renewed focus on operational efficiency. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nutrien Stock Quote
Whole Foods Market, Inc. Stock Quote
Whole Foods Market, Inc.
Allergan plc Stock Quote
Allergan plc
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.91 (-0.15%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.